Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063473 | 0.82 | HSD17B3 (0.44) | HSD17B3ALDH2KDM4EESR1ESR2 | |
| SCHEMBL1147722 | 0.82 | HSD17B3 (0.51) | HSD17B3KDM4EESR1ESR2CLK2 | |
| SCHEMBL2454830 | 0.81 | ALDH1A1 (0.50) | HSD17B3KDM4EBRD4ALDH1A1MAPT | |
| SCHEMBL25190307 | 0.80 | HSD17B3 (0.42) | HSD17B3ALDH2KDM4ETHRBESR1 | |
| SCHEMBL4058366 | 0.78 | RXFP1 (0.47) | HSD17B3KDM4EBRD4ALDH1A1MAPT | |
| SCHEMBL22010830 | 0.78 | NUAK1 (0.33) | ALDH2KDM4EADORA3ALDH1A1HPGD | |
| SCHEMBL20957619 | 0.74 | HSD17B3 (0.58) | HSD17B3KDM4EESR1ESR2CLK2 | |
| SCHEMBL5483956 | 0.71 | MAOB (0.56) | KDM4EBRD4ALDH1A1MAPTMAOB | |
| SCHEMBL17525029 | 0.70 | ALDH2 (0.59) | HSD17B3ALDH2KDM4ETHRBESR1 | |
| SCHEMBL6081605 | 0.70 | HSD17B3 (0.43) | HSD17B3KDM4EESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992479-B2 | R-fadrozole for use in the treatment of aldostonerism | DAMIAN PHARMA AG (CH) | 2024-05-28 | — | — | US | disclosed |
| US-20230047158-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20210169861-A1 | R-FADROZOLE FOR USE IN THE TREATMENT OF ALDOSTONERISM | DAMIAN PHARMA AG (CH) | 2021-06-10 | — | — | US | disclosed |
| US-20210024519-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2021-01-28 | — | — | US | disclosed |
| CN-112055590-A | R-fadrozole for the treatment of aldosteronism | 达米安制药股份公司 | 2020-12-08 | — | — | CN | disclosed |
| US-10822332-B2 | Aldosterone synthase inhibitor | DAMIAN PHARMA AG (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190292180-A1 | ALDOSTERONE SYNTHASE INHIBITOR | DAMIAN PHARMA AG (CH) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992479-B2 | R-fadrozole for use in the treatment of aldostonerism | CYP21A2, NR5A1, CYP17A1 | HSD17B3 25/4885ALDH2 160/4885KDM4E 978/4885 |
| US-20210024519-A1 | ALDOSTERONE SYNTHASE INHIBITOR | CYP21A2, CYP17A1, CYP11B1 | HSD17B3 18/4885ALDH2 929/4885KDM4E 1845/4885 |
| US-20190292180-A1 | ALDOSTERONE SYNTHASE INHIBITOR | CYP21A2, CYP17A1, CYP11B1 | HSD17B3 18/4885ALDH2 929/4885KDM4E 1845/4885 |
| US-20210169861-A1 | R-FADROZOLE FOR USE IN THE TREATMENT OF ALDOSTONERISM | CYP21A2, NR5A1, CYP17A1 | HSD17B3 25/4885ALDH2 160/4885KDM4E 978/4885 |
| US-20230047158-A1 | ALDOSTERONE SYNTHASE INHIBITOR | CYP21A2, CYP17A1, CYP11B1 | HSD17B3 18/4885ALDH2 929/4885KDM4E 1845/4885 |
| US-10822332-B2 | Aldosterone synthase inhibitor | CYP21A2, CYP17A1, CYP11B1 | HSD17B3 18/4885ALDH2 929/4885KDM4E 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.